what are the Recommendations for Selecting an Anticoagulant Regimen—
Balancing Risks and Benefits?
For patients with AF (except with moderate- to-severe mitral stenosis or a mechanical heart valve) and moderate-to-severe CKD (serum creatinine ?1.5 mg/dL [apixaban], CrCl 15 to 30 mL/min [dabigatran], CrCl ?50 mL/min [rivaroxaban], or CrCl 15 to 50 mL/ min [edoxaban]) with an elevated CHADS- 2 2 VASc score, treatment with reduced doses of direct thrombin or factor Xa inhibitors may be considered (eg, dabigatran, rivaroxaban, apixaban, or edoxaban).S4.1.1-11 MODIFIED: Exclusion criteria are now defined as moderate-to-severe mitral stenosis or a mechanical heart valve, and this recommendation has been changed in response to the approval of edoxaban. LOE was updated from C to B-R. (Section 4.1. in the 2014 AF Guideline)